D. Frye

发表

Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

G. Hortobagyi, R. Theriault, A. Buzdar, 1991, Journal of the National Cancer Institute.

p53 and c-erbB-2 expression and response to preoperative chemotherapy in locally advanced breast carcinoma

G. Hortobagyi, N. Sneige, A. Sahin, 1995 .

Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience.

G. Hortobagyi, S. Singletary, D. Booser, 1995, Surgical oncology clinics of North America.

Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience

G. Hortobagyi, N. Ibrahim, R. Theriault, 1999, Cancer Chemotherapy and Pharmacology.

Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response

Roman Rouzier, Lajos Pusztai, Terry L. Smith, 2004, Cancer.

The Role of Serum CEA as a Prognostic Indicator in Stage II and III Breast Cancer Patients Treated With Adjuvant Chemotherapy

G. Hortobagyi, R. Theriault, A. Buzdar, 1989, Cancer.

Clinical Course of Breast Cancer Patients With Metastases Limited to the Liver Treated With Chemotherapy

G. Hortobagyi, V. Valero, B. Arun, 2008, Cancer journal.

Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome.

G. Hortobagyi, N. Ibrahim, A. Buzdar, 1996, Archives of internal medicine.

Results and long term follow‐up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin‐containing chemotherapy

Terry L. Smith, G. Hortobagyi, R. Theriault, 1999, Cancer.

z-erbB2 Amplification in Node-negative Human Breast Cancer 1

Herbert, G. Hortobagyi, A. El‐Naggar, 2006 .

Recommendations for Enhancing Clinical Trials Education: a Review of the Literature

S. Cantor, T. Throckmorton, D. Frye, 2011, Journal of Cancer Education.

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.

G. Hortobagyi, A. Buzdar, R. Champlin, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

c-erbB-2 amplification in node-negative human breast cancer.

G. Hortobagyi, H. Fritsche, D. Frye, 1989, Cancer research.

Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer

G. Hortobagyi, K. Hoffman, F. Holmes, 1995, Cancer Chemotherapy and Pharmacology.

Capecitabine-based combination therapy for breast cancer: implications for nurses.

D. Frye, 2009, Oncology nursing forum.

Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.

G. Hortobagyi, H. Gibbs, V. Valero, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.

G. Hortobagyi, R. Theriault, A. Buzdar, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

New Options for Metastatic Breast Cancer

S. Mahon, D. Frye, F. Palmieri, 2009 .

Phase I Study of Vinorelbine and Docetaxel with Granulocyte Colony-Stimulating Factor Support in the Treatment of Metastatic Breast Cancer

G. Hortobagyi, V. Valero, N. Ibrahim, 2002, Cancer investigation.

A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma

G. Hortobagyi, A. Buzdar, F. Holmes, 1992, Cancer.

Primary chemotherapy for breast cancer : response to preoperative chemotherapy as prognostic factor

G. Hortobagyi, S. Singletary, F. Ames, 1994 .

First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study

G. Hortobagyi, D. Frye, M. Fridman, 2003, Breast Cancer Research.

Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.

G. Hortobagyi, L. Sutton, M. Somerville, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.

G. Hortobagyi, H. Gibbs, V. Valero, 1993, Journal of the National Cancer Institute. Monographs.

Combined modality approach in treatment of inflammatory carcinoma of the breast MD Anderson Cancer Center experience

G. Hortobagyi, R. Theriault, A. Buzdar, 1991 .

High dose oral medroxyprogesterone acetate (MPA) for the treatment of metastatic breast cancer (MBC)

G. Hortobagyi, A. Buzdar, D. Frye, 1982 .

Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.

G. Hortobagyi, V. Valero, R. Champlin, 1997, Seminars in oncology.

Pirarubicin in Combination Chemotherapy for Metastatic Breast Cancer

G. Hortobagyi, R. Theriault, A. Buzdar, 1990, American Journal of Clinical Oncology.

Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer

G. Hortobagyi, A. Buzdar, J. Gutterman, 1991, Breast Cancer Research and Treatment.

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.

Terry L. Smith, D. Berry, G. Hortobagyi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

G. Hortobagyi, A. Buzdar, G. Hortobagyi, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of Prolonged-Infusion Gemcitabine Combined with Cyclophosphamide in Patients with Metastatic Carcinoma of the Breast: Tolerability of an Optimal Dose Schedule

V. Valero, N. Ibrahim, J. Mejia, 2009, Oncology.

Advances in breast cancer treatment: the emerging role of ixabepilone

D. Frye, 2010, Expert review of anticancer therapy.

Lack of correlation between histologic findings and response to chemotherapy in metastatic breast cancer

G. Hortobagyi, D. Frye, J. Connelly, 1991, Cancer.

Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.

G. Hortobagyi, S. Singletary, F. Ames, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy

G. Hortobagyi, S. Singletary, V. Valero, 2000, Cancer.

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.

Terry L. Smith, G. Hortobagyi, S. Singletary, 2000, Journal of the National Cancer Institute.

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.

Terry L. Smith, G. Hortobagyi, L. Pusztai, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.

Terry L. Smith, D. Berry, G. Hortobagyi, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

G. Hortobagyi, S. Singletary, F. Ames, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective E valuation o f P aclitaxel V ersus C ombination Chemotherapy W ith F luorouracil, D oxorubicin, and C yclophosphamide a s N eoadjuvant T herapy i n P atients With O perable B reast C ancer

G. Hortobagyi, S. Singletary, F. Ames, 1999 .

Second-line chemotherapy for metastatic breast cancer including quality of life issues

G. Hortobagyi, V. Valero, A. Buzdar, 1996 .

Taxol in metastatic breast cancer the MD Anderson Cancer Center experience

G. Hortobagyi, H. Gibbs, V. Valero, 1994 .

Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.

K. Hess, G. Hortobagyi, L. Pusztai, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.

G. Hortobagyi, A. Buzdar, S. Legha, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inflammatory carcinoma of the breast: results of a combined-modality approach — M. D. Anderson Cancer Center experience

G. Hortobagyi, S. Singletary, F. Ames, 1990, Cancer Chemotherapy and Pharmacology.

The prognostic significance of sialyl‐tn Antigen in women treated with breast carcinoma treated with adjuvant chemotherapy

G. Hortobagyi, A. Buzdar, R. Frankowski, 1997, Cancer.

G. Hortobagyi, A. Buzdar, D. Frye, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma

G. Hortobagyi, F. Ames, A. Buzdar, 1989, Cancer.

Doxorubicin-Based Chemotherapy in Elderly Patients With Metastatic Breast Cancer: Tolerance and Outcome

G. Hortobagyi, N. Ibrahim, A. Buzdar, 1996 .

Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer a prospective, randomized trial

G. Hortobagyi, F. Ames, A. Buzdar, 1987, Cancer.

The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.

Terry L. Smith, G. Hortobagyi, S. Singletary, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy

G. Hortobagyi, V. Valero, D. Booser, 2000, Cancer.

Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature.

G. Hortobagyi, V. Valero, A. Buzdar, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized trial of high‐dose chemotherapy and autologous hematopoietic stem cell support for high‐risk primary breast carcinoma

G. Hortobagyi, S. Singletary, V. Valero, 2006, Cancer.

Secondary drug resistance in breast cancer: Failure to reverse with oral nifedipine

G. Hortobagyi, F. Holmes, D. Frye, 1997, International journal of cancer.

A Phase I and Pharmacokinetic Study of TAS-108 in Postmenopausal Female Patients with Locally Advanced, Locally Recurrent Inoperable, or Progressive Metastatic Breast Cancer

V. Valero, D. Booser, R. Theriault, 2004, Clinical Cancer Research.

Phase I study of eniluracil and oral 5‐fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma

G. Hortobagyi, V. Valero, D. Booser, 2002, Cancer.

Phase I clinical study of nafazatrom

G. Hortobagyi, J. Ajani, J. Reuben, 2004, Investigational New Drugs.

Twelve-year follow-up of a randomized trial of high-dose chemotherapy (HDC) and autologous hematopoietic stem cell support (ASCS) for high-risk primary breast carcinoma

G. Hortobagyi, S. Singletary, V. Valero, 2005 .

Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy.

G. Hortobagyi, L. Pusztai, S. Singletary, 2001, Cancer journal.

Phase I Study of Prolonged-Infusion Gemcitabine Combined with Cyclophosphamide in Patients with Metastatic Carcinoma of the Breast: Tolerability of an Optimal Dose Schedule

V. Valero, N. Ibrahim, J. Mejia, 2009, Oncology.

Capecitabine-based combination therapy for breast cancer: implications for nurses.

D. Frye, 2009, Oncology nursing forum.